Phase 4 Atrial Fibrillation Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- Adults aged 19 years or older at the time of screening
- People whose atrial fibrillation (an irregular heart rhythm) has been confirmed by a heart tracing (ECG) during screening and at the baseline visit
- People who have a stroke risk score (called CHA2DS2-VASc) of 1 or more for men, or 2 or more for women, meaning blood-thinning medication would typically be recommended for them
- People whose kidneys are working at a sufficient level, measured by a creatinine clearance rate of 50 ml/min or higher
- People who are willing to give written consent to take part in the study
Who may not be able to join:
- People who have moderate narrowing of the mitral heart valve, or who have had a mechanical (artificial) heart valve
- People who have certain other conditions affecting hormone-producing glands (such as thyroid, adrenal, parathyroid, or pancreatic disease) that may contribute to atrial fibrillation
- People who have experienced a clinically significant bleeding event, such as bleeding in the brain or gastrointestinal tract
- People who have significant liver disease that affects blood clotting, including Child-Pugh Class B or C liver disease
- People considered at increased risk of bleeding due to any of the following: a stomach or intestinal ulcer in the past 6 months; bleeding in or around the brain in the past 6 months; abnormal blood vessels in the spine or brain; brain, spinal cord, or eye surgery in the past 30 days; brain or spinal cord injury in the past 6 months; confirmed or suspected enlarged veins in the oesophagus (food pipe); abnormal connections between arteries and veins (arteriovenous malformation); a vascular aneurysm; or a cancer considered to carry a high risk of bleeding
- People who have had a stroke or a temporary stroke-like episode (transient ischaemic attack) that required treatment with a combination of blood-thinning and anti-platelet medications, or who are being treated for a recent heart attack requiring such a combination
- People who have had an allergic or adverse reaction to rivaroxaban or any of its ingredients
- People who have certain rare genetic conditions affecting how the body processes galactose or glucose (such as galactose intolerance, Lapp lactase deficiency, or glucose-galactose malabsorption)
- People with uncontrolled high blood pressure, where the top reading is above 180 mmHg or the bottom reading is above 100 mmHg
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jong-il Choi, MD, PHD, Korea University
Phone: 02-920-6710
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Incident rate of major bleeding events
Can't join this trial?
Data last synced from ClinicalTrials.gov: 22 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.